Monitor BP in Patients on Injectable CGRP Antagonists (Aimovig, Etc)

You’ll hear concerns about using an injectable CGRP antagonist (Aimovig, etc) for migraine prophylaxis in patients with CV risks.

Most data suggest that CGRP antagonists have minimal CV impact. But it’s mostly short-term data in young patients without CV risks.

Now an FDA review suggests new-onset or worsening hypertension with Aimovig (erenumab)...prompting labeling updates.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote